“$49 vs. $199”: the price war has begun
In February 2026, U.S. telehealth company Hims & Hers Health sent a jolt through the global pharmaceutical market. The compounded semaglutide pill it launched costs $49 (about KRW 70,000)for the first month and then $99 (about KRW 140,000)a month, a radical price point. That is less than half the $199 (about KRW 280,000) a month for the brand-name Wegovy pill.
On the news, Novo Nordisk shares plunged 6%, showing how shaken the market was. Novo Nordisk immediately called it “illegal mass compounding” and threatened legal action, but the market’s doubts about an “oligopoly” whose true face had already been exposed could no longer be contained.
Two sides of a $70 billion market: a goose that lays golden eggs vs. a patent swamp
The global obesity drug market reached $70 billion (about KRW 95 trillion) in 2025 and is expected to grow to $100 billion (about KRW 143 trillion)by 2030.
Surging from $15 billion in 2024 to $70 billion in 2025, it posted annual growth of 367%, an explosive pace.
Novo Nordisk: 75% revenue growth in three years and a legendary 45% operating margin
Table
Copy
| Year | Revenue (in $100 millions) | Operating profit (in $100 millions) | Net profit (in $100 millions) | Operating margin |
|---|---|---|---|---|
| 2022 | 177 | 69 | 56 | 39.2% |
| 2023 | 232 | 105 | 84 | 45.3% |
| 2024 | 290 | 129 | 101 | 44.4% |
| 2025 | 309 | 135 | 102 | 43.6% |
Novo Nordisk’s revenue surged 75% over three years, writing a “profit legend” for the pharma industry. In particular, its 2024 operating profit of $12.9 billionwas up 33.6% from the year before, and its operating margin of 44.4%shows profitability that outshines tech companies.
But the outlook for 2026 is grim. Novo Nordisk expects its 2026 revenue to fall 5–13%, and its shares plunged on the news.
It reflects a combination of intensifying competition in the obesity drug market and pressure from the U.S. government to cut drug prices.
Eli Lilly: Zepbound lifts it to No. 2, with 2026 revenue forecast at $80 billion
Table
Copy
| Year | Revenue (in $100 millions) | Operating profit (in $100 millions) | Net profit (in $100 millions) | Operating margin |
|---|---|---|---|---|
| 2022 | 285 | 71 | 62 | 25.0% |
| 2023 | 341 | 70 | 52 | 20.6% |
| 2024 | 450 | 135 | 106 | 29.9% |
| 2025 | 652 | 170 | 106 | 26.1% |
In 2024, Eli Lilly saw Zepboundgrow explosively, lifting revenue 45% year over year. It set 2026 revenue guidance at $80–83 billion, confidently beating the market consensus ($77.6 billion).
UBS kept its 2026 revenue forecast for Eli Lilly at $83.2 billionand set a price target of $1,250.
Cantor Fitzgerald raised its price target from $985 to $1,205 and kept its “overweight” rating.
The start of the 2026 patent expirations: the moment the monopoly crumbles
But a shadow is falling over this golden age. 2026, patents on GLP-1 drugs begin to expire in major countries.
- Semaglutide (Wegovy/Ozempic): patents expire in 2026 in China, India, Brazil, Türkiye and Canada
- U.S. and Europe: protected until the early 2030s, but pressure from copycat drugs is building in earnest
This is not just a date on a calendar. The moment patents lapse, dozens of copycat drugswill flood the market, and prices are likely to crash to 10–20% of current levels. Hims’ $49 pill is merely a “preview” that brings this future forward.
K-bio strikes back: is a Korean GLP-1 possible?
Korean biotech companies are not mere bystanders in the GLP-1 war. But the reality is tough.
Why can’t Korea make a GLP-1 drug?
- Patent barriers: the core patents on semaglutide and tirzepatide are valid into the 2030s, and developing a new compound that gets around them would take trillions of won in R&D and more than 10 years.
- Technology gap: long-acting technology for peptide drugs (extending half-life) and oral formulation technology (improving absorption) are areas monopolized by Novo Nordisk and Eli Lilly.
- Economies of scale: Phase 3 trials require at least hundreds of billions of won, which most Korean biotechs are structurally unable to afford.
But there are gaps: “formulation innovation” and “multi-agonists”
Instead of a head-on fight, Korean companies are pursuing improved formulations andand multi-agonistsas a breakthrough.Table
Copy
| Company | Pipeline | Features | Stage |
|---|---|---|---|
| Hanmi Pharmaceutical | Efpeglenatide | GLP-1/GCG dual agonist | Applied for Korean marketing approval (December 2025); launch planned for the second half of 2026 |
| D&D Pharmatech | DD01 | GLP-1/GCG receptor agonist | In Phase 2 trials in the U.S. |
| D&D Pharmatech | DD02S (using ORALINK) | Oral GLP-1 with better absorption than Rybelsus | Phase 1; technology transfer to Metsera completed |
| Peptron | Microsphere formulation | Extends dosing from once a week to once a month | Joint research with Eli Lilly |
| Inventage Lab | IVL-DrugFluidic | Once-monthly long-acting formulation | Joint research with Boehringer Ingelheim |
| Ildong Pharmaceutical | ID110521156 | Oral small-molecule GLP-1 | Phase 1 completed; up to 13.8% weight loss after four weeks of dosing |
| Raphas | Microneedle patch | Painless transdermal formulation | In development |
Hanmi Pharmaceutical’s efpeglenatideis the first GLP-1 obesity drug developed in Korea and is set to launch in the second half of 2026. It is drawing attention for weight loss comparable to global Big Pharma drugs (up to 15% in Phase 2 trials).
Insurance coverage and price cuts: the future of the Korean market
Wegovy and Mounjaro are currently prescribed in Korea without national health insurance coverage, and the actual prices patients pay are as follows:Table
Copy
| Drug | Dose | 4-week (1-month) supply price | Actual patient cost (including prescription fee) |
|---|---|---|---|
| Wegovy | 0.25mg | KRW 210,000–220,000 | About KRW 230,000–250,000 |
| Wegovy | 2.4mg | KRW 370,000 | About KRW 400,000–450,000 |
| Mounjaro | 2.5mg | KRW 278,000 | About KRW 300,000–350,000 |
| Mounjaro | 5mg | KRW 369,000 | About KRW 400,000–450,000 |
| Mounjaro | 7.5mg+ | KRW 521,000 | About KRW 550,000–600,000 |
In August 2025, in response to Mounjaro’s launch, Wegovy cut its price by up to 42%, and at the starting dose (0.25mg) it is now actually cheaper than Mounjaro.
When will insurance cover it?
- Second half of 2026–2027: after Hanmi Pharmaceutical launches efpeglenatide, national health insurance coverage may follow a health technology assessment (HTA)
- Current situation: some private indemnity insurance may apply when prescribed for diabetes, but use for obesity treatment is entirely uncovered
Price decline scenarios
Table
Copy
| Scenario | Timing | Expected price (per 4 weeks) | Market impact |
|---|---|---|---|
| Now | 2025 | KRW 210,000–600,000 | Accessible to the middle class; costs over KRW 1 million a year |
| Korean drug launches | 2026–2027 | KRW 150,000–400,000 | Price competition heats up; market grows 2–3 times |
| Copycat drugs take off | 2030 | KRW 50,000–150,000 | Goes mainstream; market grows 5–10 times |
Key change: if today’s KRW 200,000–600,000 a month falls to KRW 50,000–150,000, annual treatment costs will drop from KRW 2.4–7.2 million to KRW 0.6–1.8 million. At that price, not just the middle class but also value-conscious consumers can enter the market.
Korean biotech stock outlook: who will lead?
Price targets and ratings for beneficiaries
Table
Copy
| Company | Brokerage | Target | Rating | Key catalysts |
|---|---|---|---|---|
| Hanmi Pharmaceutical | Hana Securities | KRW 640,000 | Buy | Efpeglenatide launch (second half of 2026); hopes for technology transfer deals |
| Hanmi Pharmaceutical | Meritz Securities | KRW 620,000 | Buy | Multiple obesity and metabolic catalysts |
| Hanmi Pharmaceutical | Kyobo Securities | KRW 510,000(already exceeded) | Buy | Hopes for partner pipelines at JPM |
| D&D Pharmatech | Yuanta Securities | Not set | Not Rated | Validation of ORALINK technology; Metsera trial results |
| Peptron | Expert views | KRW 330,000–385,000 | Buy | Hopes the Eli Lilly technology evaluation deal becomes a full contract |
Hanmi Pharmaceuticalhas an average brokerage price target of KRW 532,500, and Hana Securities, based on 2027 EBITDA, applied an EV/EBITDA multiple of 14.8 timesand set KRW 640,000as its price target.
This implies 18.3%of further upside from the current share price.
D&D Pharmatechmust prove the value of its ORALINK platform technology. LS Securities expressed optimism, calling 2025 “the year to prove the value of its oral platform.”
Peptroncould, if its technology evaluation deal with Eli Lilly becomes a full contract, see its shares rise two- to threefold , analysts expect. Experts are offering price targets in the KRW 330,000–385,000 range.
BITPRESS Insight: beyond the “innovator’s dilemma”
Hims’ $49 challenge is not just a price war. It is a symbolic event that illustrates the “innovator’s dilemma”. Novo Nordisk and Eli Lilly invested billions of dollars to develop GLP-1 drugs and have enjoyed outsized profits in return. But now their success has produced a paradox: unequal access.
Who will win in the future?
- Generic and copycat drugmakers: they will benefit first in China and India, where patents start expiring in 2026. Names to watch include China’s Heoswi Pharmaceuticaland India’s Sun Pharma .
- Next-generation platform companies: the survivors will be companies that innovate rather than simply imitate, with oral formulations,, once-monthly long-acting drugs, Microneedle patch . In Korea, D&D Pharmatech’s ORALINK and Raphas’ patch technology fit this description.
- Digital health care platforms: telehealth companies such as Hims will go beyond supplying drugs to build a “weight management ecosystem”and create added value. Drugmakers will struggle to follow them there.
K-bio’s real opportunity
For Korean biotech companies, GLP-1 should be a chance not to “catch up” but to “leapfrog”. It is already too late to copy semaglutide. Instead, they need to transform the user experience with “peptides you can swallow,”, “once-a-month injections,”, “painless patches” and similar innovations.
If Korean companies capture just 10% of the $100 billion market in 2030, that is $10 billion (about KRW 14 trillion)in revenue, roughly equal to the total exports of Korea’s entire pharmaceutical industry today.
“An expensive drug is not innovation. A drug everyone can use is innovation.” It is time for K-bio to answer the question posed by Hims’ $49 challenge.
This article is for informational purposes only and is not investment advice. Investment decisions should be made at your own judgment and responsibility.
